Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens

被引:2
|
作者
Hariri, Nosaibah [1 ]
Hasteh, Farnaz [1 ]
Walavalkar, Vighnesh [1 ]
Roma, Andres A. [1 ]
Fadare, Oluwole [1 ]
机构
[1] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
关键词
repeat testing; estrogen receptor; progesterone receptor; human epidermal growth factor receptor-2; IN-SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; CORE-NEEDLE; CLINICAL ONCOLOGY/COLLEGE; PROTEIN EXPRESSION; AMERICAN SOCIETY; HER2; DISCORDANCE; ER; RECOMMENDATIONS;
D O I
10.1097/PAI.0000000000000525
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
At some tertiary breast care centers, where many patients are referred from other institutions, it is routine to repeat testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/neu) in excision specimens if these tests were performed on the preceding biopsy at the referring facility. The goal of this study is to assess the value of this practice. We documented results from ER, PR, and HER2 testing in 541 consecutive invasive breast cancers excised over a 2.5-year period and analyzed the subset (n=153) for which testing was performed on the excision specimen solely due to the fact that testing on the preceding biopsy was performed at an outside institution. The rates and directions of biopsy-to-excision change were as follows: ER [1.3% (2/153), 100% from (+) to (-)]; PR [4% (6/153), 83% from (+) to (-)]; HER2/neu assessed by immunohistochemistry [21% (29/137)]; HER2/neu assessed by fluorescence in situ hybridization [3.3% (2/61); 50% from amplified to nonamplified and 50% vice versa]. There were no ER(-) and PR(-) biopsy cases that became ER and/or PR(+) in the excision. By coordinate analysis for the hormone receptors [ie, ER and/or PR(+) being indicative of "hormone receptor" (HR) positivity], there were no cases that changed from HR(+) in the biopsy to HR(-) in the excision (or vice versa), which suggests that repeat testing for ER and PR in this setting is of limited value. In an analysis that incorporated both immunohistochemistry and in situ fluorescence hybridization results, there were 2 cases with a clinically significant biopsy-to-excision change in HER2/neu status in which that change was detected primarily because the excision was retested. These findings provide baseline data for formulating policies on whether repeat testing should routinely be performed in the described scenario.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [1] Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression Rates in Invasive Breast Carcinoma
    Mais, Daniel D.
    Nazarullah, Alia N.
    Guidi, Anthony J.
    Dintzis, Suzanne
    Blond, Barbara J.
    Long, Thomas A.
    Coulter, Suzanne N.
    Brown, Richard W.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2025, 149 (01) : 8 - 13
  • [2] Reflex Estrogen Receptor/Progesterone Receptor/Human Epidermal Growth Factor Receptor 2 (ER/PR/Her2) Analysis of Breast Cancers in Needle Core Biopsy Specimens Dramatically Increases Health Care Costs
    VandenBussche, Christopher J.
    Cimino-Mathews, Ashley
    Park, Ben Ho
    Emens, Leisha A.
    Tsangaris, Theodore N.
    Argani, Pedram
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (07) : 939 - 947
  • [3] The diagnostic value of BI-RADS grade 3 to 5 for breast masses is correlated with the expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2
    He, Tiejun
    Shi, Tiemei
    Luo, Wendong
    Ju, Yabo
    Li, Ran
    MEDICINE, 2023, 102 (26) : E33208
  • [4] Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer
    Qin Qinghong
    Gao Fangfang
    Jiang Wei
    Tan Qixing
    Mo Qinguo
    Wei Changyuan
    CHINESE MEDICAL JOURNAL, 2014, 127 (18) : 3272 - 3277
  • [5] Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
    S. Subramaniam
    N. Bhoo-Pathy
    N. A. Taib
    G. H. Tan
    M. H. See
    S. Jamaris
    G. F. Ho
    L. M. Looi
    C. H. Yip
    World Journal of Surgery, 2015, 39 : 2450 - 2458
  • [6] Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients
    Zhao, Xingjuan
    Yang, Xuan
    Fu, Lei
    Yu, Keda
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4579 - 4586
  • [7] Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
    Subramaniam, S.
    Bhoo-Pathy, N.
    Taib, N. A.
    Tan, G. H.
    See, M. H.
    Jamaris, S.
    Ho, G. F.
    Looi, L. M.
    Yip, C. H.
    WORLD JOURNAL OF SURGERY, 2015, 39 (10) : 2450 - 2458
  • [8] Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
    Rakha, Emad A.
    Pigera, Marian
    Shin, Sandra J.
    D'Alfonso, Timothy
    Ellis, Ian O.
    Lee, Andrew H. S.
    HISTOPATHOLOGY, 2016, 69 (01) : 20 - 24
  • [9] Molybdenum Target X-Ray Features and Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 in Invasive Breast Cancer
    Tailaiti, Gulijire
    Maimaiti, Gulanbaier
    Aikeremu, Youlituzi
    Tuerdi, Batuer
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 2777 - 2783
  • [10] Evaluation of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Status Before and After Neoadjuvant Chemotherapy in Breast Cancer Patients
    Adarsh Verma
    Amrita Ghosh Kar
    Ram Niwas Meena
    S. C. U. Patne
    Shashi Prakash Mishra
    Seema Khanna
    Rahul Khanna
    Indian Journal of Surgery, 2021, 83 : 399 - 403